Fleury S.A.

São Paulo Stock Exchange FLRY3.SA

Fleury S.A. EBIT for the year ending December 31, 2023: USD 210.99 M

Fleury S.A. EBIT is USD 210.99 M for the year ending December 31, 2023, a 37.26% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.
  • Fleury S.A. EBIT for the year ending December 31, 2022 was USD 153.72 M, a 23.52% change year over year.
  • Fleury S.A. EBIT for the year ending December 31, 2021 was USD 124.45 M, a 30.93% change year over year.
  • Fleury S.A. EBIT for the year ending December 31, 2020 was USD 95.05 M, a -31.72% change year over year.
  • Fleury S.A. EBIT for the year ending December 31, 2019 was USD 139.20 M, a 6.48% change year over year.
Key data
Date EBIT EBITDA Net Income EPS (Diluted)
Market news
Loading...
São Paulo Stock Exchange: FLRY3.SA

Fleury S.A.

CEO Ms. Jeane Mike Tsutsui
IPO Date Dec. 17, 2009
Location Brazil
Headquarters Avenida General Valdomiro de Lima, 508
Employees 27,000
Sector Health Care
Industries
Description

Fleury S.A., together with its subsidiaries, provides medical services in the diagnostic, treatment, clinical analysis, health management, medical care, orthopedics, and ophthalmology areas in Brazil. The company operates through three segments: Diagnostic Medicine, Integrated Medicine, and Dental. It provides laboratory and image exam, diagnostic information, check-up and reference laboratory, genomics, clinic day, center of infusions, dental imaging exam, dental radiology, and diagnostic imaging services. The company also offers Saúde I, a digital healthcare platform that provides services, including teleconsultations, medical, diagnostic medicine exams, and procedures; and corporate solutions and face-to-face primary care, as well as solutions for physicians with digital office and medical education. It operates 284 customer service units and 31 hospital-based units under the Labs a+, Felippe Mattoso, Lafe, Fleury, a+SP, CIP, Moacir Cunha, Vita, inlab, Weinmann, Serdil, a+ and Diagmax, a+, IRN / CPC, Diagnosis a+, a+BA, and Pretti and Bioclinic brand names. The company was founded in 1926 and is headquartered in São Paulo, Brazil.

Similar companies

ABEV3.SA

Ambev S.A.

USD 1.85

0.28%

EGIE3.SA

Engie Brasil Energia S.A.

USD 5.71

0.61%

MDIA3.SA

M. Dias Branco S.A. Indústria e Comércio de Alimentos

USD 3.22

1.38%

WEGE3.SA

WEG S.A.

USD 8.71

-0.05%

StockViz Staff

January 15, 2025

Any question? Send us an email